Acadia falls after Alzheimer's-related drug narrowly misses goal in study

By Reuters News

** Acadia Pharmaceuticals ACAD.O shares fall 15.6% to $21.45 premarket

** Co says its experimental drug remlifanserin narrowly missed main goal in mid-stage trial

** The study tested remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP)

** Company says trends suggest continuing development of 60 mg once-daily dose in ADP

** Acadia plans to continue enrolling its two ongoing late-stage studies evaluating remlifanserin in ADP

** Alzheimer's disease psychosis involves experiencing hallucinations and delusions driven by physical brain changes

** Up to last close, stock down ~5% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.